This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Modafinil for sleep disorders and fatigue secondary to multiple sclerosis: a review of the clinical efficacy and safety
. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012
No conclusions can be drawn on the efficacy of modafinil compared to methylphenidate or amphetamines due to the absence of head-to-head clinical trials. Relative to placebo, modafinil was associated with improvements in sleepiness and some domains of health related quality of life, in patients with narcolepsy however, the clinical importance of these findings are unclear. No clear benefit was found with modafinil in patients with fatigue related to MS. The data available were insufficient to draw conclusions on the safety of modafinil in patients with sleep disorders or MS.
Subject indexing assigned by CRD
Benzhydryl Compounds; Fatigue; Humans; Multiple Sclerosis; Sleep Wake Disorders
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, K1S 5S8 Ottawa, Ontario Canada Email: email@example.com
Date abstract record published